Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
Basildon (UK), 20 July, 2021 – m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil. This portfolio is comprised of well-known established brands for the treatment of cardiovascular, nervous system, and rheumatological illnesses. The main goal of the partnership is to continue to strengthen the positioning of these products, providing continued support to physicians and ensuring access to the patients in the territory. These original medicines continue to be essential tools in the treatment for their respective indications. This collaboration reinforces m8 Pharmaceuticals’ and Pharmanovia’s mutual focus to strengthen the presence of their medicines in Latin America, bringing innovative and proven treatments with greater access to patients and caregivers throughout the region.
According to IQVIA, the market size of Latin America’s pharmaceutical industry is projected to continue growing in the upcoming years. Currently, Mexico & Brazil makes up about 2/3 of the total pharmaceutical market in Latin America, which is valued at over 45 billion dollars. The portfolio includes Valium®, Rocaltrol®, Inderalici®, Tenormin®, Tenoretic®, Zestril® & Zestoretic®
“We are committed to serve doctors, caregivers and patients by providing them with a holistic portfolio of original market-leading brands and innovative pharmaceuticals. We are delighted to strengthen our strategic partnership with Pharmanovia in the region” said Joel Barlan, m8’s CEO.
Regarding the collaboration Amit Patel, Pharmanovia’s CEO said “Having had the pleasure of working with the M8 team in the past, we are looking forward to this extended collaboration that strengthens our position in Latin America. We firmly believe our continued partnership will positively impact the benefit of patient health in the territory.”
About M8 PHARMACEUTICALS
m8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico. m8 aims to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, Respiratory, Cardiometabolic, Rheumatology, Gastroenterology, Onco-hematology and Orphan Diseases. m8 is a Montreux Equity Partners portfolio company.
For more information, please visit: www.moksha8.com or contact:
Chief Executive Officer
T: +52 (55) 4431 2933
Vice President of Corporate Development
T: +1 (305) 299 6998
About Pharmanovia – The original medicines specialist globally
Our purpose is to progress iconic medicines for the benefit of patient health globally. We provide iconic, tried and trusted medicines in the strategic therapeutic areas of Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology. We own some of the world’s most recognisable brands, including Bonviva®, Inderal®, Kytril®, Naprosyn®, Valium®, Zestril® and more. We operate a portfolio of 20+ brands in 140+ markets with over 200 employees, and we grow through development, licensing and acquisition.
For further information: pharmanovia.com
Pharmanovia Press Contact
Kate Antonopoulos, Corporate Marketing & Communications Manager
Phone: +44 1268 943857